Samuel Huber

Dr. Samuel Huber\'s background is in the field of gastroenterology/immunobiology. He graduated in April 2006 and obtained the Board Certification for Medicine. Dr. Huber did his residency in the Department of Gastroenterology, University Medical Center Hamburg-Eppendorf, Germany (chairman, Prof. A.W. Lohse). From 2008 to 2012, Dr. Huber did his postdoctoral training at Richard A. Flavell’s lab in the Department of Immunobiology, School of Medicine, Yale University, USA. Currently, he is leading the Section of Molecular Gastroenterology and Immunology at the I. Medical Department, University Medical Center Hamburg-Eppendorf, Germany. The main focus of the lab is to study the mechanism controlling the homeostasis in the intestine in order to identify new therapeutic targets for the treatment of inflammatory bowel disease and colorectal cancer.

1books edited

1chapters authored

Latest work with IntechOpen by Samuel Huber

The incidence of chronic inflammatory and autoimmune diseases is steadily increasing. Inflammatory bowel disease (IBD) is one example of a chronic inflammatory disease, which primarily affects the intestine but may also affect extraintestinal organs. The exact pathogenesis of IBD is currently unknown. However, it is clear that the pathogenesis is complex, involving barrier defects, changes in the intestinal microbiome, and chronic immune activation. This book aims to summarize basic aspects of these complex interactions between barrier function, microbiome, and the immune system. Of note, there is currently no cure for IBD. However, several therapies have evolved in the last years, which are overall able to-at least temporarily-suppress IBD. These therapies and the underlying mechanism are discussed.

Go to the book